Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria.

Aims: This work describes the encapsulation of ceftazidime and tobramycin in zein nanoparticles (ZNPs) and the characterization of their antibacterial and antibiofilm activities against Gram-negative bacteria. Materials & methods: ZNPs were synthesized by nanoprecipitation. Cytotoxicity was assessed by MTT assay and antibacterial and antibiofilm assays were performed by broth microdilution and violet crystal techniques. Results: ZNPs containing ceftazidime (CAZ-ZNPs) and tobramycin (TOB-ZNPs) showed drug encapsulation and thermal stability. Encapsulation of the drugs reduced their cytotoxicity 9-25-fold. Antibacterial activity, inhibition and eradication of biofilm by CAZ-ZNPs and TOB-ZNPs were observed. There was potentiation when CAZ-ZNPs and TOB-ZNPs were combined. Conclusion: CAZ-ZNPs and TOB-ZNPs present ideal physical characteristics for in vivo studies of antibacterial and antibiofilm activities.

A nanotechnology product was developed to treat diseases caused by bacteria. This prototype showed the ideal characteristics and could be administered by ingestion through the mouth, aspiration through the nose or injection into the veins. The prototype did not harm or kill human cells. It killed the bacteria and prevented the formation of a type of protection against antibiotics that bacteria can produce, called a biofilm. Nanotechnology products are a promising alternative for the treatment of bacterial infections.

Supramolecular interactions between ß-lapachone with cyclodextrins studied using isothermal titration calorimetry and molecular modeling.

Supramolecular interactions between ß-lapachone (ß-lap) and cyclodextrins (CDs) were investigated by isothermal titration calorimetry. The most favorable host: guest interaction was characterized using X-ray powder diffraction (XRD), differential scanning calorimetry and thermogravimetry (DSC/TG), spectroscopy (FT-IR), spectroscopy (2D ROESY) nuclear magnetic resonance (NMR), and molecular modeling. Phase solubility diagrams showed ß-, HP-ß-, SBE-ß-, γ-, and HP-γ-CDs at 1.5% (w/w) allowed an increase in apparent solubility of ß-lap with enhancement factors of 12.0, 10.1, 11.8, 2.4, and 2.2, respectively. ß-lap has a weak interaction with γ- and HP-γ-CDs and tends to interact more favorably with ß-CD and its derivatives, especially SBE-ß-CD (K = 4160 M-1 ; ΔG = -20.66 kJ·mol-1 ). Thermodynamic analysis suggests a hydrophobic interaction associated with the displacement of water from the cavity of the CD by the ß-lap. In addition, van der Waals forces and hydrogen bonds were responsible for the formation of complexes. Taken together, the results showed intermolecular interactions between ß-lap and SBE-ß-CD, thereby confirming the formation of the inclusion complex. Molecular docking results showed 2 main orientations in which the interaction of benzene moiety at the wider rim of the SBE-ß-CD is the most stable (average docking energy of -7.0 kcal/mol). In conclusion, ß-lap:SBE-ß-CD is proposed as an approach for use in drug delivery systems in cancer research.

Encapsulation into Stealth Liposomes Enhances the Antitumor Action of Recombinant Cratylia mollis Lectin Expressed in Escherichia coli.

This study evaluated the in vivo antitumor potential of the recombinant lectin from seeds of Cratylia mollis (rCramoll) expressed in Escherichia coli, free or encapsulated in stealth liposomes, using mice transplanted with sarcoma 180. rCramoll-loaded stealth liposomes (rCramoll-lipo) were formulated by hydration of the lipid film followed by cycles of freezing and thawing, and about 60% of rCramoll was encapsulated. This novel preparation showed particle size, polydispersity index, and pH suitable for the evaluation of antitumor activity in vivo. Tumor growth inhibition rates were 59% for rCramoll and 75% for rCramoll-lipo. Histopathological analysis of the experimental groups showed that both free and encapsulated lectin caused no changes in the kidneys of animals. Hematological analysis revealed that treatment with rCramoll-lipo significantly increased leukocyte concentration when compared with the untreated and rCramoll group. In conclusion, the encapsulation of rCramoll in stealth liposomes improves its antitumor activity without substantial toxicity; this approach was more successful than the previous results reported for pCramoll loaded into conventional liposomes. At this point, a crucial difference between the antitumor action of free and encapsulated rCramoll was found along with their effects on immune cells. Further investigations are required to elucidate the mechanism(s) of the antitumor effect induced by rCramoll.

Molecular modeling and cytotoxicity of diffractaic acid: HP-ß-CD inclusion complex encapsulated in microspheres.

In this pioneer study, 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) was used to improve the solubility of the diffractaic acid (DA) via inclusion complex (DA:HP-ß-CD). Subsequently, DA:HP-ß-CD was incorporated into poly-ε-caprolactone (PCL) microspheres (DA:HP-ß-CD-MS). Microspheres containing DA (DA-MS) or DA:HP-ß-CD (DA:HP-ß-CD-MS) were prepared using the multiple W/O/W emulsion-solvent evaporation technique. The phase-solubility diagram of DA in HP-ß-CD (10-50mM) showed an AL type curve with a stability constant K1:1=821M-1. 1H NMR, FTIR, X-ray diffraction and thermal analysis showed changes in the molecular environment of DA in DA:HP-ß-CD. The molecular modeling approach suggests a guest-host complex formation between the carboxylic moiety of both DA and the host (HP-ß-CD). The mean particle size of the microspheres were ∅DA-MS=5.23±1.65µm and ∅DA:HP-ß-CD-MS=4.11±1.39µm, respectively. The zeta potential values of the microspheres were ζDA-MS=-7.85±0.32mV and ζDA:HP-ß-CD-MS=-6.93±0.46mV. Moreover, the encapsulation of DA:HP-ß-CD into microspheres resulted in a more slower release (k2=0.042±0.001; r2=0.996) when compared with DA-MS (k2=0.183±0.005; r2=0.996). The encapsulation of DA or DA:HP-ß-CD into microspheres reduced the cytotoxicity of DA (IC50=43.29µM) against Vero cells (IC50 of DA-MS=108.48µM and IC50 of DA:HP-ß-CD-MS=142.63µM).

Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates.

Mycobacterium tuberculosis (Mtb) has acquired resistance and consequently the antibiotic therapeutic options available against this microorganism are limited. In this scenario, the use of usnic acid (UA), a natural compound, encapsulated into liposomes is proposed as a new approach in multidrug-resistant tuberculosis (MDR-TB) therapy. Thus the aim of this study was to evaluate the effect of the encapsulation of UA into liposomes, as well as its combination with antituberculous agents such as rifampicin (RIF) and isoniazid (INH) against MDR-TB clinical isolates. The in vitro antimycobacterial activity of UA-loaded liposomes (UA-Lipo) against MDR-TB was assessed by the microdilution method. The in vitro interaction of UA with antituberculous agents was carried out using checkerboard method. Minimal inhibitory concentration values were 31.25 and 0.98 µg/mL for UA and UA-Lipo, respectively. The results exhibited a synergistic interaction between RIF and UA [fractional inhibitory concentration index (FICI) = 0.31] or UA-Lipo (FICI = 0.28). Regarding INH, the combination of UA or UA-Lipo revealed no marked effect (FICI = 1.30-2.50). The UA-Lipo may be used as a dosage form to improve the antimycobacterial activity of RIF, a first-line drug for the treatment of infections caused by Mtb.

Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates

Mycobacterium tuberculosis (Mtb) has acquired resistance and consequently the antibiotic therapeutic options available against this microorganism are limited. In this scenario, the use of usnic acid (UA), a natural compound, encapsulated into liposomes is proposed as a new approach in multidrug-resistant tuberculosis (MDR-TB) therapy. Thus the aim of this study was to evaluate the effect of the encapsulation of UA into liposomes, as well as its combination with antituberculous agents such as rifampicin (RIF) and isoniazid (INH) against MDR-TB clinical isolates. The in vitro antimycobacterial activity of UA-loaded liposomes (UA-Lipo) against MDR-TB was assessed by the microdilution method. The in vitro interaction of UA with antituberculous agents was carried out using checkerboard method. Minimal inhibitory concentration values were 31.25 and 0.98 µg/mL for UA and UA-Lipo, respectively. The results exhibited a synergistic interaction between RIF and UA [fractional inhibitory concentration index (FICI) = 0.31] or UA-Lipo (FICI = 0.28). Regarding INH, the combination of UA or UA-Lipo revealed no marked effect (FICI = 1.30-2.50). The UA-Lipo may be used as a dosage form to improve the antimycobacterial activity of RIF, a first-line drug for the treatment of infections caused by Mtb.

Nanoencapsulation of quercetin and resveratrol into elastic liposomes.

Based on the fact that quercetin (QUE) and resveratrol (RES) induce a synergic inhibition of the adipogenesis and increase apoptosis in adipocytes, and that sodium deoxycholate (SDC) has necrotic effects, the nanoencapsulation of QUE and RES into SDC-elastic liposomes is proposed as a new approach for dissolving the subcutaneous fat. The concentration of constituents and the effect of the drug incorporation into cyclodextrin inclusion complexes on the stability of QUE/RES-loaded liposomes were studied. The best liposomal formulation reduced the use of phosphatidylcholine and cholesterol in 17.7% and 68.4%, respectively. Liposomes presented a mean diameter of 149nm with a polydispersion index of 0.3. The zeta potential of liposomes was slightly negative (-13.3mV) due to the presence of SDC in the phospholipid bilayer. Encapsulation efficiency of QUE and RES into liposomes was almost 97%. To summarize, QUE/RES-loaded elastic liposomes are stable and suitable for subcutaneous injection, thereby providing a new strategy for reducing subcutaneous fat.

Radiolysis of 2-[¹8F]fluoro-2-deoxy-D-glucose ([¹8F]FDG) and the role of ethanol, radioactive concentration and temperature of storage.

The 2-[(18)F]-fluoro-2-deoxy-d-glucose ([(18)F]FDG) undergoes radiolysis under high temperature and concentration of activity in the absence of stabilizers. No studies on the influence of transport temperature and concentrations of ethanol, used as stabilizer, higher than 0.1% in the radiolytic stability of [(18)F]FDG are reported. In the present work, [(18)F]FDG samples with activity concentrations between 20 and 130 mCi/mL and with concentrations of 0.1-0.4% ethanol remained stable over 16 h, regardless of storage temperature (5, 25 or 40°C).

Enhanced antiproliferative activity of the new anticancer candidate LPSF/AC04 in cyclodextrin inclusion complexes encapsulated into liposomes.

LPSF/AC04 (5Z)-[5-acridin-9-ylmethylene-3-(4-methyl-benzyl)-thiazolidine-2,4-dione] is an acridine-based derivative, part of a series of new anticancer agents synthesized for the purpose of developing more effective and less toxic anticancer drugs. However, the use of LPSF/AC04 is limited due to its low solubility in aqueous solutions. To overcome this problem, we investigated the interaction of LPSF/AC04 with hydroxypropyl-ß-cyclodextrin (HP-ß-CyD) and hydroxypropyl-γ-cyclodextrin (HP-γ-CyD) in inclusion complexes and determine which of the complexes formed presents the most significant interactions. In this paper, we report the physical characterization of the LPSF/AC04-HP-CyD inclusion complexes by thermogravimetric analysis, differential scanning calorimetry, infrared spectroscopy absorption, Raman spectroscopy, (1)HNMR, scanning electron microscopy, and by molecular modeling approaches. In addition, we verified that HP-ß-CyD complexation enhances the aqueous solubility of LPSF/AC04, and a significant increase in the antiproliferative activity of LPSF/AC04 against cell lines can be achieved by the encapsulation into liposomes. These findings showed that the nanoencapsulation of LPSF/AC04 and LPSF/AC04-HP-CyD inclusion complexes in liposomes leads to improved drug penetration into the cells and, as a result, an enhancement of cytotoxic activity. Further in vivo studies comparing free and encapsulated LPSF/AC04 will be undertaken to support this investigation.

Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product.

Amphotericin B remains the drug of choice for the treatment of most of the systemic fungal infections in immunodeficient patients. Because of the high incidence of adverse drug reactions the clinical use of Amphotericin B is rather limited. To reduce its toxicity new drug delivery systems has been suggested. Nevertheless, these carriers present several technological drawbacks that impair the development of a marketable product. The aim of this work was to develop an Amphotericin B microemulsion in order to increase its efficacy and decrease its toxicity compared to Fungizon, the widely know inexpensive micellar system of Amphotericin B. Amphotericin B loaded microemulsion showed an average size close to 300 nm by photon correlation spectroscopy. In the UV spectrum, the observation of the monomeric peak at 405 nm, which was independent of the sample dilution, revealed that the Amphotericin B molecules were strongly and individually bound to the microemulsion droplets. The new microemulsion formulation had the same efficacy than Fungizon against C. albicans. Concerning toxicity, Amphotericin B loaded microemulsion showed lower toxicity against human red blood cells compared to the commercial product. Taken together, these results suggested that microemulsion is an eligible drug carrier for Amphotericin B or other water insoluble molecules, and it has potential applications to targeting fungal cells. Additionally, a novel formulation of Amphotericin B-loaded microemulsion was prepared by a straightforward and fast procedure.

The encapsulation of ß-lapachone in 2-hydroxypropyl-ß-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach.

The aim of this study was to encapsulate lapachone (ß-lap) or inclusion complex (ß-lap:HPß-CD) in liposomes and to evaluate their physicochemical characteristics. In addition, the investigation of the main aspects of the interaction between ß-lap and 2-hydroxypropyl-ß-cyclodextrin (HPß-CD), using both experimental and molecular modeling approaches was discussed. Furthermore, the in vitro drug release kinetics was evaluated. First, a phase solubility study of ß-lap in HPß-CD was performed and the ß-lap:HPß-CD was prepared by the freeze-drying technique. A 302-fold increase of solubility was achieved for ß-lap in HPß-CD solution with a constant of association K(1:1) of 961 M(-1) and a complexation efficiency of ß-lap of 0.1538. (1)H NMR, TG, DSC, IR, Raman and SEM indicated a change in the molecular environment of ß-lap in the inclusion complex. Molecular modeling confirms these results suggesting that ß-lap was included in the cavity of HPß-CD, with an intermolecular interaction energy of -23.67 kJ mol(-1). ß-lap:HPß-CD and ß-lap-loaded liposomes presented encapsulation efficiencies of 93% and 97%, respectively. The kinetic rate constants of 183.95±1.82 µg/h and 216.25±2.34 µg/h were calculated for ß-lap and ß-lap:HPß-CD-loaded liposomes, respectively. In conclusion, molecular modeling elucidates the formation of the inclusion complex, stabilized through hydrogen bonds, and the encapsulation of ß-lap and ß-lap:HPß-CD into liposomes could provide an alternative means leading eventually to its use in cancer research.

In vitrouptake and antimycobacterial activity of liposomal usnic acid formulation.

The cellular uptake and antimycobacterial activity of usnic acid (UA) and usnic acid-loaded liposomes (UA-LIPOs) were assessed on J774 macrophages. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of UA and UA-LIPO against Mycobacterium tuberculosis were determined. Concentrations required to inhibit 50% of cell proliferation (IC(50)) were 22.5 (+/-0.60) and 12.5 (+/-0.26) microg/ml, for UA and UA-LIPO, respectively. The MICs of UA and UA-LIPO were 6.5 and 5.8 microg/mL, respectively. The MBC of UA-LIPO was twice as low (16 microg/mL) as that of UA (32 microg/mL). An improvement in the intracellular uptake of UA-LIPO was found (21.6 x 10(4) +/- 28.3 x 10(2) c.p.s), in comparison with UA (9.5 x 10(4) +/- 11.4 x 10(2) c.p.s). In addition, UA-LIPO remains much longer inside macrophages (30 hours). All data obtained from the encapsulation of usnic acid into liposomes as a drug delivery system (DDS) indicate a strong interaction between UA-liposomes and J774 macrophages, thereby facilitating UA penetration into cells. Considering such a process as ruling the Mycobacterium-transfection by magrophages, we could state that associating UA with this DDS leads to an improvement in its antimycobacterial activity.

Elucidation of the complexation mechanism between (+)-usnic acid and cyclodextrins studied by isothermal titration calorimetry and phase-solubility diagram experiments.

In the present work the complexation mechanism between (+)-usnic acid (UA) and cyclodextrins (CDs) has been investigated by isothermal titration calorimetry (ITC) and phase-solubility diagrams using pH as a tool for modifying the molecule ionization. ITC experiments have been employed to evaluate the stoichiometry of interaction (N), affinity constants (K), and thermodynamic parameter variation associated with complexation between (+)-UA and alpha-, beta-, HP-beta-, SBE-beta-, and gamma-CD. It was shown that (+)-UA did not interact with alpha-CD and tended to interact more favorably with gamma-CD (K = 1030 M(-1), DeltaG = -17.18 kJ x mol(-1)) than beta-CD (K = 153 M(-1), DeltaG = -12.46 kJ x mol(-1)) forming 1:1 complexes. It was also demonstrated using ITC and solubilization experiments that chemical modifications of the parent beta-CD resulted in stronger and more spontaneous interactions (K = 281 M(-1), DeltaG = -13.97 kJ x mol(-1) for SBE-beta-CD and K = 405 M(-1), DeltaG = -14.87 kJ x mol(-1) for HP-beta-CD). Analysis of the thermodynamic data suggested that van der Waals forces and hydrogen bonds were responsible for the formation of complexes with a predominance of van der Waals forces. Finally, pH induced modifications of (+)-UA ionization provided important informations relative to the topology of the interaction between (+)-UA molecule and the gamma-CD cavity, which were confirmed by molecular modeling.

Comparison of the interfacial properties of Eugenia uniflora and Triticum vulgaris lectins.

We have investigated the interfacial and dielectric properties of EuniSL, a recently purified lectin obtained from seeds of Eugenia uniflora (EuniSL), through surface pressure (Pi) and surface potential (DeltaV) measurements of its floating monolayers at the 2.0

Encapsulation and release characteristics of DCTN/PLGA microspheres.

In the present study, poly (D,L-lactic-co-glycolic)-acid microspheres containing trans-Dehydrocrotonin (DCTN) were prepared by the double emulsion method. The hypoglycemic activity of DCTN-loaded microspheres was monitored in normal glycemic mice after administration of a daily dose of DCTN (50 mg kg(-1) body weight) for 7 days. Spherical microspheres with two populations of particles with 3.20 +/- 0.10 and 7.60 +/- 0.70 microm mean diameter size microm were observed. The encapsulation efficiency of DCTN was 85.5 +/- 3.9%. The in vitro kinetic profile of DCTN from PLGA-microspheres was initially fast (burst effect of 19.4% at 2 h). Such a burst step was maintained until achieving 35.7+/-2.0% at 7h, followed by a gradual release of DCTN attaining a maximum drug release at 55.7 +/- 2.6% within 30 h. DCTN was able to reduce glucose levels (14.3%) of normal glycemic animals and this effect was improved by its encapsulation into microspheres (26.8%). The optimum glucose levels in the blood of animals treated with DCTN suspension and DCTN-loaded microspheres were 119.21 +/- 19.75 mg dL(-1) at day 5 and 103.08 +/- 18.88 mg dL(-1) at day 7, respectively. DCTN-loaded microspheres are thus offered as a potential delivery system for the treatment of metabolic diseases characterized by hyperglycemia.

Thermodynamic characterization of the prevailing molecular interactions in mixed floating monolayers of phospholipids and usnic acid.

The investigation of the characteristics of mixed floating monolayers of phospholipids and usnic acid (UA), an active metabolite from lichens, can provide valuable information on how to prepare stable liposomes that could serve as carriers of UA for therapeutic proposes. The present paper is concerned with the thermodynamic analysis of the behavior of Langmuir monolayers formed by mixing different phospholipids (dibehenoylphosphatidylcholine, DBPC, dipalmitoylphosphatidylcholine, DPPC, and dioleoylphosphatidylcholine, DOPC) and UA at varied molar fractions. Relevant thermodynamic parameters such as excess areas, excess free energies and free energy of mixing were derived from the surface pressure data obtained from compression measurements performed in a Langmuir trough. For the largest lateral pressure examined (25 mN/m), negative values of the excess free energy were found only for the DOPC/UA monolayer, which should be the most stable of them. Based on the calculated values of the free energy of mixing, we note that the DBPC/UA and DPPC/UA systems present the best mixed character at low pressures and when the molar fraction of the UA is 0.5; at that relative concentration and at low values of the external pressure, the UA molecules can better mix and interact with the phospholipid molecules. The compression isotherms for mixed monolayers show no visible transitions, exhibiting a more organized phase that corresponds to a negative free energy of mixing. We have established that the most stable monolayers were those corresponding to DOPC/UA mixtures with a UA molar fraction of 0.75.

Usnic acid: a non-genotoxic compound with anti-cancer properties.

The majority of human tumors bear inactive p53 or cellular factors that down-regulate the expression and activity of the p53 network. Therefore, finding therapies that are effective in such tumors is of great interest. Usnic acid, a normal component of lichens, showed activity against the wild-type p53 breast cancer cell line MCF7 as well as the non-functional p53 breast cancer cell line MDA-MB-231 and the lung cancer cell line H1299 (null for p53). In MCF7 cells treated with usnic acid, although there was an accumulation of p53 and p21 proteins, the transcriptional activity of p53 remained unaffected. We also found that there was no phosphorylation of p53 at Ser15 after treatment of MCF7 cells with usnic acid, suggesting that the oxidative stress and disruption of the normal metabolic processes of cells triggered by usnic acid does not involve DNA damage. The property of usnic acid as a non-genotoxic anti-cancer agent that works in a p53-independent manner makes it a potential candidate for novel cancer therapy.

Mixed monolayers of Bauhinia monandra and concanavalin A lectins with phospholipids, part II.

Isotherms of surface pressure and surface potential versus mean molecular area for dibehenoylphosphatidylcholine (DBPC), dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylethanolamine (DPPE), and dioleoylphosphatidylcholine (DOPC) monolayers were shown to be greatly modified when these lipids were cospread with either Bauhinia monandra (BmoLL) or Concanavalin A (Con A) lectins. For the binary films of DBPC, DPPC, and DPPE cospread with each of these two lectins, there was both a displacement of the Pi-A and DeltaV-A isotherms toward higher molecular areas relative to pure lipids and an increase in the maximum surface potential values relative to the DeltaV-A relationships observed for the corresponding single-lectin systems. Both effects can be understood in terms of the occurrence of an explicit interaction between the lipids and the lectins. The plots of the corresponding compressibilities versus molecular areas reveal that, for all lipids but DOPC, the extent of this interaction was always larger for BmoLL than for Con A. The DPPC and DPPE mixed films with BmoLL differed in compressibility. Owing to the small DPPE polar headgroup, the DPPE-BmoLL film was much more incompressible than the DPPC-BmoLL mixed monolayer. However, for the DOPC-BmoLL and DOPC-Con A mixed films there was no evidence that an interaction between the lectins and the lipid took place, a fact attributed to the unsaturated character in the DOPC aliphatic chains, which leads to an expanded Pi-A isotherm.

Dielectric properties of Bauhinia monandra and concanavalin A lectin monolayers, part I.

The dielectric properties of the galactose-binding lectins Bauhinia monandra (BmoLL) and Concanavalin A (Con A) were assessed by surface potential measurements of their spread monolayers on an aqueous subphase containing a monovalent electrolyte. For both lectins the curves of surface potential versus mean molecular area (DeltaV-A) and the independently recorded isotherms of surface pressure versus mean molecular area (Pi-A) were shown to be pH-dependent. As the subphase pH changed from 2 to 9, a noticeable trend to higher surface pressures accompanied the compression of the monolayers. Conversely, the surface potentials values of both monolayers decreased with increasing pH. For Con A, with the single exception of the pH 9 case, lowering the pH yielded DeltaV values higher than those for BmoLL. The contribution of the electric double layer (Psi0) to the overall DeltaV values at a given Pi (15 mN/m) was calculated using a modified Davies equation and assuming that at this surface pressure the monolayers of both studied lectins were stable. While at all studied pHs the Psi0 values for Con A exceeded those calculated for BmoLL, for both lectins they were insensitive to pH changes. This provided evidence that the reorientation of lectin molecules, during compression predominantly contributed to the alteration of the overall DeltaV values. The calculated Psi0 values made possible the evaluation of the dipole moments for BmoLL and Con A, and it has been estimated that the decrease in the pH of the subphase from 9 to 2 produced a 1.6-fold (twofold) increase in the value of for BmoLL (Con A). The differences in dielectric properties between the two film-forming lectins have been attributed to the differences in their structures. Indeed, the circular dichroism (CD) spectrum of Con A showed the predominance of beta-plated sheet structures while that of BmoLL was typically rich in alpha-helix structures.

Antitumor activity of Cratylia mollis lectin encapsulated into liposomes.

The hemagglutinating (HA) activity of Cratylia mollis lectin (Cra) was evaluated and the influence of ultrasound and mechanical agitation on its activity examined. The antitumor activity of Cra-loaded liposomes was also investigated. Liposomes were obtained by the lipid thin film method. Physicochemical characterization was carried out and long-term stability of Cra-loaded liposomes assessed. Antitumor activity of Cra-loaded liposomes was investigated against Sarcoma 180 in Swiss mice. The treatment was performed intraperitoneally (7 mg/kg body weight per day) for 7 days. Histopathological analyses of tumor, liver, spleen and kidneys were carried out after treatment of the animals. The results showed that Cra-HA activity is affected under ultrasound exposure. However, Cra was successfully encapsulated into liposomes and the activity of the lectin was preserved despite the use of ultrasound in the liposome preparation. Cra-loaded liposomes were produced with an 84% encapsulation ratio (700 microg/ml) and a tumor inhibition of 71% was achieved. The encapsulation of Cra produced a decrease in its tissue toxicity and improved its antitumor activity. In particular, histopathological analysis revealed that treatment with Cra-loaded liposomes prevented Cra cytotoxicity in the liver and kidney of animals.